Both Acadia Pharmaceuticals and e-therapeutics pulled back the curtain this week on new looks for their respective corporate brand identities.
E-therapeutics was the more drastic makeover of the two. The company reintroduced itself Wednesday as Tangram Therapeutics, inspired by the eponymous geometric puzzles “in which differently shaped pieces can be arranged in countless ways to create something greater.”
In that way, according to the company, the new name reflects how Tangram is combining biological insights, artificial intelligence, a proprietary chemistry platform and its team of scientists to rapidly develop new RNAi medicines.
The relaunch comes as Tangram prepares to submit its first clinical trial application in the fourth quarter of this year for its lead candidate, TGM-312, in metabolic dysfunction-associated steatohepatitis.
Along with the updated look and name, Tangram also unveiled its applied AI platform, LLibra OS, which analyzes human disease models and other datasets to identify, evaluate and design potential new drug candidates. The company said the updated technology, which was built on its previous computational platform, will help it make better decisions earlier in the drug development process, allowing it to reduce risk and accelerate the overall process.
“Our relaunch today as Tangram Therapeutics represents far more than a new name,” CEO Ali Mortazavi said in the announcement. “It reflects the company we have become—one that unites proven expertise in AI, biology and chemistry with a clear focus on developing RNAi medicines.”
Mortazavi added: “By combining these elements, we are better equipped to identify targets, design effective medicines and accelerate their path to patients. This bold strategy allows us to diverge from the crowded therapeutic hypotheses being extensively pursued in biopharma and offer differentiated options to patients and carers.”
Acadia, meanwhile, is holding on to its national-park-inspired name, while brightening up its logo.
The rare disease drugmaker’s logo previously featured a serene circle next to the all-caps Acadia name, all done up in a placid blue gradient. Its new look is bolder, with darker text and an orange sunburst replacing the circle symbol.
Acadia CEO Catherine Owen Adams wrote on the company’s website that the new brand identity reflects its work so far to develop medicines for underserved patients and also “expresses our hope for the future: one that is bright, purposeful and visionary, defined by the relentless pursuit of transformative science.”
The rebrand is “optimistic and grounded in expertise,” Owen Adams continued, and “is a promise to patients, caregivers and clinicians that we will never lose sight of the human side of science.”
The CEO noted that the brand update “sets the stage” for the company’s “next era,” in which it will build on its previous work creating new treatments for neurological conditions—including Parkinson’s disease-related psychosis med Nuplazid and Rett syndrome treatment Daybue—to expand into other rare disease areas. Acadia’s pipeline currently includes candidates in Alzheimer’s disease- and Lewy body dementia-associated psychosis, major depressive disorder, Huntington’s disease and more.